Posts by Maggie Beller

Profile of the SeptiCyte™ LAB gene expression assay to diagnose infection in critically ill patients.

Sepsis is a severe and frequently occurring clinical syndrome, caused by the inflammatory response to infections. Recent studies on the human transcriptome during sepsis have yielded several gene-expression assays that might assist physicians during clinical assessment of patients suspected of sepsis. SeptiCyte™ LAB (Immunexpress, Seattle, WA) is the first gene expression assay that was cleared…

Read More

Immunexpress Appoints Jane Papadaki Markley as VP of Market Development and Commercial Operations

Immunexpress.com

The addition represents the development of a global commercial framework in preparation for SeptiCyte™ RAPID launch Immunexpress, Inc. today announced that Jane Papadaki Markley has joined the company’s Executive Team as Vice President of Market Development and Commercial Operations. “Jane’s impressive ability to incorporate the commercial perspective into development strategies will be influential in our upcoming launch…

Read More

Novacyt, Immunexpress Extend Sepsis Assay Development Partnership

French diagnostics firm Novacyt said today that its molecular testing division Primerdesign has extended its sepsis assay development contract with Immunexpress.   Specific terms of the deal were not disclosed.   Novacyt said the companies have been working together for three years, with Primerdesign providing Immunexpress with assay development services. In 2017, Seattle-based Immunexpress received…

Read More

Disagreement in Sepsis Diagnosis is Associated with Significant Antibiotic Overprescription

Immunexpress.com

Immunexpress, Inc., a molecular diagnostics company based in Seattle, announced the publication of a study, in the Journal of Intensive Care, demonstrating the challenge physicians face in making accurate and consistent clinical diagnoses of sepsis in intensive care patients. Sepsis is an illness caused by the body’s overwhelming immune response to an infection, which can lead to tissue…

Read More

Immunexpress Wins $745K HHS Contract for Rapid Sepsis Assay

Immunexpress said today that it has received a funding commitment of $744,739 from the US Department of Health and Human Services (HHS) for the development and commercialization of its SeptiCyte sample-to-result sepsis assay.   The RT-qPCR assay, which received US Food and Drug Administration 510(k) clearance in early 2017, is designed to rapidly differentiate infection-positive…

Read More

Immunexpress Secures BARDA Contract for the Continued Development of SeptiCyte™ for the Rapid and Accurate Diagnosis of Sepsis

Immunexpress.com

Immunexpress, Inc. today announced its partnership with the DRIVe Solving Sepsis Initiative, a collaboration in which DRIVe will contribute $744,739 of a $3.2M project for the development and commercialization of Immunexpress’ SeptiCyte™ technology on the Biocartis Idylla™ platform. This development will result in a tool capable of a 90-minute, sample-to-result diagnosis in patients suspected of sepsis. DRIVe (Division of…

Read More

Future In A Flash – Rollie Carlson CEO of Immunexpress

As the JP Morgan Healthcare Conference convenes in San Francisco, we’re offering a glimpse into the future of the industry, from the C-suites of the most promising pharma, biopharma, medtech, tech and telehealth companies in the nation. Today we explore the latest trends in rapid diagnostics with Immunexpress CEO, Rollie Carlson in this Future in…

Read More